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Abstract
Background: Pregnancy malaria is caused by Plasmodium falciparum-infected erythrocytes binding the placental receptor
chondroitin sulfate A (CSA). This results in accumulation of parasites in the placenta with severe clinical consequences for the
mother and her unborn child. Women become resistant to placental malaria as antibodies are acquired which specifically target
the surface of infected erythrocytes binding in the placenta. VAR2CSA is most likely the parasite-encoded protein which
mediates binding to the placental receptor CSA. Several domains have been shown to bind CSA in vitro; and it is apparent that
a VAR2CSA-based vaccine cannot accommodate all the CSA binding domains and serovariants. It is thus of high priority to define
minimal ligand binding regions throughout the VAR2CSA molecule.
Methods: To define minimal CSA-binding regions/peptides of VAR2CSA, a phage display library based on the entire var2csa
coding region was constructed. This library was screened on immobilized CSA and cells expressing CSA resulting in a limited
number of CSA-binding phages. Antibodies against these peptides were affinity purified and tested for reactivity against CSA-
binding infected erythrocytes.
Results: The most frequently identified phages expressed peptides residing in the parts of VAR2CSA previously defined as CSA
binding. In addition, most of the binding regions mapped to surface-exposed parts of VAR2CSA. The binding of a DBL2X peptide
to CSA was confirmed with a synthetic peptide. Antibodies against a CSA-binding DBL2X peptide reacted with the surface of
infected erythrocytes indicating that this epitope is accessible for antibodies on native VAR2CSA on infected erythrocytes.
Conclusion: Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined. A number of these
regions localize to CSA-binding domains and to surface-exposed regions within these domains and a synthetic peptide
corresponding to a peptide sequence in DBL2 was shown to bind to CSA and not to CSC. It is likely that some of these epitopes
are involved in native parasite CSA adhesion. However, antibodies directed against single epitopes did not inhibit parasite
adhesion. This study supports phage display as a technique to identify CSA-binding regions of large proteins such as VAR2CSA.
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Background
PAM (Pregnancy Associated Malaria) is a major health
problem in malaria-endemic areas and on a world basis it
affects millions of pregnant women and their offspring.
The presence of parasites in the placenta of pregnant
women can have serious consequences for both mother
and child including: maternal anaemia, premature deliv-
ery, low birth weight and increased infant mortality [1]. In
malaria endemic areas, children acquire clinical immu-
nity after multiple infections, and adults are in general
protected against malaria. Women who have acquired
immunity against malaria during childhood become sus-
ceptible to malaria during pregnancy due to novel parasite
phenotypes expressing unique antigens not encountered
during childhood infections [2,3]. In areas of high para-
site transmission PAM mainly affects primigravidae since
immunity is acquired as a function of gravidity [1]. Protec-
tive antibodies target proteins expressed on the surface of
infected erythrocytes (IE), which mediate binding to syn-
cytiotrophoblasts. By this process, the parasite is not fil-
tered through the spleen and thus avoids exposure to
effector mechanisms, which clear erythrocytes infected
with late blood stage parasite from circulation [4]. The
best characterized surface protein is the Plasmodium falci-
parum erythrocyte membrane protein 1 (PfEMP1) [5,6],
which is encoded by the polymorphic var gene family con-
taining 50–60 copies per parasite genome [7]. The
PfEMP1 family constitutes high-molecular proteins of
200–400 kDa, which are highly polymorphic. Different
PfEMP1 molecules have different receptor specificities,
therefore switching between expression of various var
genes in a mutually exclusive manner allows the parasite
to modify its adhesion properties (reviewed in [8]).
PfEMP1 proteins include three to seven Duffy-binding-
like (DBL) domains, which belong to a parasite adhesion-
domain super-family present in erythrocyte invasion lig-
ands called: erythrocyte-binding ligands (EBL). Antibod-
ies against PfEMP1 can interfere with parasite binding and
the successive acquisition of a broad range of PfEMP1
antibodies is important for the acquisition of immunity
during childhood [9-13]. Several molecules such as
ICAM-1 [14], VCAM-1 [15], thrombospondin [16], CD36
[17], and chondroitin sulfate A (CSA) [18,19] have been
identified as host receptors for PfEMP1. In the placenta IE
exclusively bind to the glycosaminoglycan CSA [19,20].
The parasite protein mediating IE adhesion to CSA in the
placenta is a distinct member of the PfEMP1 protein fam-
ily, named VAR2CSA [21]. High levels of anti-VAR2CSA
antibodies are correlated with favourable birth outcome
and they are acquired as a function of parity [22]. Disrup-
tion of the var2csa gene causes the loss of the IE's ability to
bind CSA [23]. VAR2CSA is a large IE surface-expressed
antigen consisting of six DBL domains with a total esti-
mated molecular mass of 350 kDa. The ultimate aim of
PAM vaccine development is to define a VAR2CSA con-
struct capable of eliciting antibodies that inhibit binding
of IEs to CSA. However, several of the VAR2CSA domains
have in vitro affinity to CSA [24-26] and this complicates
vaccine design. It is thus of high priority to define the min-
imal epitopes within each domain and inter-domains that
have affinity to CSA.
Phage display is a strong and widely used tool for map-
ping protein ligand interactions and has in several studies
been used to define adhesive parts of proteins present on
the surface of different organisms causing infectious dis-
eases (reviewed in [27]). Phage display has also been
extensively used in malaria research. For vaccine develop-
ment Casey and others [28], used phage display to isolate
a phage-derived peptide that mimic an important epitope
of AMA-1 and had the ability to induce functionally pro-
tective antibodies. Lanzillotti and others [29], used a
phage display library to search for P. falciparum encoded
motifs involved in erythrocyte invasion, and identified
regions in EBA-175 and Ebl-1 like proteins binding to
receptors on the human erythrocyte. EBA and Ebl belong
to the same super family of Duffy-binding-like proteins as
the DBL domains from VAR2CSA. We were thus encour-
aged to use this technique to search for CSA-binding
motifs in VAR2CSA. In this study a phage display library
was constructed based on the exon1 coding region of
VAR2CSA. The library was biopanned on different sources
of glycosaminoglycans (GAG) including: immobilized
bovine CSA; immobilized proteoglycans purified from
placentas – CSPG; CSA-expressing CHO cells, and BeWo
cells derived from the human placental syncytiotrophob-
lasts. Five regions of VAR2CSA potentially involved in in
vivo parasite sequestration were identified and are thus
potential candidate components of a multivalent PAM
vaccine.
Methods
Cells
The human choriocarcinoma cell line BeWo was pur-
chased from the American Type Culture Collection [30].
The cells were maintained in Ham's F12 with L-glutamine
culture medium (Lonza, Verviers, Belgium) supple-
mented with 10% FCS and 1% penicilin/streptavidin
(Sigma-Aldrich, Ayshire, UK). Chinese Hamster ovary
cells (CHO) were maintained in RPMI1640 (with L-
glutamine and 25 mM HEPES) (Lonza, Verviers, Belgium)
suplemented with 10% FCS and 1% penicilin/streptavi-
din.
Construction of the var2csa phage display library
The exon1 of var2csa was digested with DNase1 (Sigma-
Aldrich, Brøndby, Denmark) and fragments of 100 bp–
150 bp were ligated into the T7select 415-1b vector
(Novagen Inc., Madison, USA) at EcoRI and HindIII sites.Malaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
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Phage packaging amplification and titration were per-
formed according to the manufacturer's instructions [31].
Selection of the GAG binding phages from T7var2csa 
library
Different approaches to select for phages binding to CSA
were used. Common to these approaches was the general
procedure for selection of clones, which consisted in four
rounds of biopanning, followed by infection of E. coli
(BL21) with the selected phages. The bacteria were plated
and individual plaques were amplified and sequenced.
(1) Phage selection on human choriocarcinoma cell line
BeWo or CHO cell line:
BeWo/CHO cells were cultured in Nuclon™ delta surface
(Nunc, Roskilde, Denmark) 6 well-plates until confluent.
The plates were incubated for 15 minutes at 4°C before
adding 1 × 109 plaque forming units (pfu) T7var2csa
phages to the cells for 1 hour at 37°C. The cells were then
washed carefully four times in pre-warmed 1% Bovine
Serum Albumin (BSA) in PBS for five minutes per wash.
The bound phages were eluted in 1 ml of 0.2 M glycin pH
6 for 10 minutes. The eluted phages were amplified to
ensure a titer of 109 pfu for input phages at the start of
each successive round.
(2) Phage selection on biotinylated CSA
CSA (C9819 Sigma-Aldrich, Brøndby, Denmark) was
biotinylated using EZ-Link Sulfo-NHS-LC-Biotinylation
kit (Pierce, Bonn, Germany). 100 μl of 50 μg/ml bioti-
nylated CSA in PBS was added to pre-coated avidin plates
(Nunc, Roskilde, Denmark) for 1 hour at room tempera-
ture and the wells were subsequently blocked with 200 μl
of 1% BSA in PBS for 1 hour. After washing the plates
three times with PBS, 1 × 109 pfu of T7var2csa phages were
added to the plate for 1 hour at 37°C. The wells were then
washed twice in round 1, three times in round 2, and five
times in subsequent rounds with TBS 0.5 % Tween-20 for
3 minutes. The phages were eluted in 100 μl of 0.1 M gly-
cin pH 2.2 for 10 minutes, neutralized immediately with
6 μl of 2 M Tris base pH 8 and added to fresh log-phase
BL21 cells.
(3) Phage selection on human placenta derived chondroi-
tin sulfate proteoglycans (CSPG) [32] or bovine CSA
(Sigma). Proteoglycan (5 μg/ml in PBS) was coated to
microtiter plates (Nunc, Roskilde, Denmark) overnight at
4°C. The following steps were done as described for bioti-
nylated CSA.
PCR amplification of plaques
A portion of top agarose of an individual plaque of inter-
est was scrapped by a pipette tip, dispersed in a tube con-
taining 100 μl of 10 mM EDTA, and heated at 65°C for 10
min. The plaques collected served as templates in a PCR
reaction with primers for the T7 vector supplied by the
manufacturer (Novagen, Madison, USA). 15 μl of the
reaction product was analysed on a 1% agarose gel. For
sequencing, the PCR product was purified by Minielute
purification kit (Qiagen) and 4 μl of pure PCR product
was used in the sequencing reaction.
Peptide synthesis
Peptides were synthesized by Schafer-N, Århus, Denmark
(P2c, P3, P4 and P5) or Sigma (P1, P2a, P2b) (Table 1).
Peptides P1, P2a, b, c and P5 were synthesized with the
addition of a terminal cystein for increased stability. P2
region is very long and difficult to synthetize and was
therefore divided into two peptides P2a and P2c. P2b cor-
respondes to the P2a region and has the FCR3 isolate
sequence. PC is a non-VAR2CSA peptide and it was used
as a negative control (Table 1). Peptide identity and purity
were analysed by MALDI-TOF mass spectrometry and
high-performance liquid-chromatography (HPLC). The
synthesized peptide sequences are shown in one-letter
code (Table 1).
Biotinylation of peptides
All peptides were biotinylated using EZ-link Sulfo-NHS-
LC-Biotin (Pierce, Bonn, Germany) following the instruc-
tions for preferentially biotinylation of N-terminal α-
amino groups in peptides [33].
Table 1: Amino acid sequence of the synthetic peptides identified by phage display
Peptide ID Protein ID Sequence
P1 3D7 – DBL1X ENQKNKYTELYQQNKC
P2a 3D7 – DBL2X GKKTQELKNIRTNSELLKEWIIAAFHEGKC
P2b FCR3 – DBL2X EDVKDINFDTKEKFLAGCLIVSFHEGKC
P2c 3D7 – DBL2X LKPSHEKKNDDNGKKLCKAC
P3 3D7 – DBL3X IKKIIEKGTTKQNGKTVGSGAEN
P4 3D7 – DBL4ε IKNKNDITNAKKELLETLQIVAERE
P5 3D7 – DBL5ε ILKGAQSEGKFLGNYYNEDKDKEKALEAMC
PC P. falciparum Potassium pump WRRDTYNMIWGFNKIPTYIYNMLLILLSTSYIDMalaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
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GAG binding ELISA
Flat-bottomed, 96 well plates (Falcon 351172) were
coated for 2 hours at 37°C either with CSA (C9819 Sigma-
Aldrich, Brøndby, Denmark) 50 μg/ml in PBS; CSC (shark
cartilage, Seikagaku, Tokyo, Japan) 50 μg/ml in PBS; or
only PBS (as a negative control). The plates were then
blocked for 1 hour at 37°C with 1% BSA, 0.05% Tween
20, in PSM buffer (PBS, 2 mM CaCl2, 2 mM MgCl2, pH 7).
After two times washing with 0.05% Tween 20 in PSM
buffer, 50 μl of a dilution series (0.4 – 25 μg/ml) of pep-
tide in blocking buffer was added per well and incubated
overnight at 4°C. After three times washing, 50 μl of a 1/
2000 dilution of a streptavidin-conjugated horseradish
peroxidase antibody (Dako, Glostrup, Denmark) in
blocking buffer was added to each well and incubated at
37°C for one hour. The binding assay was finalized with
three times washing and developing with 100 μl/well of o-
phenylenediamine substract for 10 minutes. Plates were
read at 490 nm. The curves (Figure 3A) are typical of four
independent experiments, and each absorbance value is
the mean of two experiments. Figure 3B absorbance val-
ues are the result of one experiment.
Affinity purification of peptide-specific rabbit antibodies
Affinity purification of antibodies was done according
tomanufacturer's instructions. In brief, 0,5 mg of peptide
was dialyzed against 0.2 M NaHCO3, 0.5 M NaCl (pH
8.3), and applied to a NHS-activated HiTrap 1-ml column
(GE Healthcare) that had been equilibrated with 3 × 2 ml
1 mM HCl. After coupling, the column was washed with
0.5 M ethanolamine, 0.5 M NaCl (pH 8), 0.1 M acetate,
0.5 M NaCl (pH 4), and a final wash with PBS (pH 7.4).
3 ml of rabbit antisera against the specific domain [34]
was subsequently added to the column. After washing in
10 ml PBS, affinity-bound antibodies were eluted by
CH3COONH4 (pH 3) and neutralized in 1 M Tris (pH
7.5). The specificity of the purified antibodies was tested
in ELISA against (1) the peptide used for affinity purifica-
tion, and (2) other VAR2CSA peptides. The affinity-puri-
fied antibodies were only positive against the VAR2CSA
peptides on which they had been affinity purified.
A DBL2 peptide binds to CSA and not to CSC Figure 3
A DBL2 peptide binds to CSA and not to CSC. (A) Peptide binding assay to CSA: P2b (red) binds to CSA (n) in a peptide 
concentration-specific manner and not to the plate (s). The control peptide (blue) does not bind to neither the plate (×) nor 
CSA (). (B) Peptide binding assay to CSC: P2b (red) does not bind to either CSC (n) or to the plate (s). The control peptide 
(blue) does not bind to neither the plate (×) nor CSC ().
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Parasite culture and selection
The NF54 laboratory strain of P. falciparum was used. Par-
asite culture was done as previously described [34]. The
genotype of the parasite was regularly checked by GLURP
and MSP2-specific primers in a single PCR step.
To create a VAR2CSA-expressing parasite population, the
NF54 parasites were repeatedly panned on VAR2CSA-spe-
cific antibodies creating the NF54var2csa  parasite line.
Briefly, late stage trophozoites were obtained by gelatin
purification and washed twice in RPMI1640. The IE were
then incubated for 0.5 hour at 37°C with VAR2CSA-
DBL5ε-specific rabbit antiserum and washed three times
with medium to remove unbound antibodies. IE express-
ing VAR2CSA were isolated by the use of protein G-cou-
pled magnetic beads (Dynal, Invitrogen) on a MACS
magnet (Miltenyi Biotec). The suspension of IE and beads
was washed three times and added to a culture flask with
4% hematocrit of uninfected erythrocytes in 5 ml culture
medium. After 24 hours, the beads were removed by mag-
netic separation. This was repeated until parasites specifi-
cally expressed VAR2CSA on the surface. Expression of the
VSAPAM phenotype was confirmed by specific binding of
parasites to CSA in static binding assays, and exclusive rec-
ognition of the surface of the IE by antibodies from
women exposed to P. falciparum during pregnancy.
Flow cytometry and IFA
Flow cytometry was used to test if the peptide-specific
antibodies recognize the surface of CSA-binding IEs. Par-
asite cultures (NF54VAR2CSA) were enriched to contain
>75% erythrocytes infected by late trophozoite and sch-
izont stage parasites by exposure to a strong magnetic field
[35]. Aliquots (2 × 105 IE) were labeled by ethidium bro-
mide (to allow exclusion of remaining uninfected erythro-
cytes). For IE surface staining with rabbit anti-peptide IgG,
samples were sequentially exposed to 20 μl sera followed
by 1 μl biotinylated sheep-anti-rabbit IgG (The Binding
Site, Birmingham, UK) and to 0.5 μl streptavidin-FITC
(BD Pharmingen, San Diego, US). All incubations were
performed in a total volume of 100 μl PBS with 2% FCS
for 30 minutes. Samples were washed two times with 3 ml
PBS, 2% FCS between each incubation. Data from a min-
imum of 5000 IE were acquired using a FC500 flow
cytometer (Beckman Coulter, Ramcon, Denmark). For
each sample, the mean fluorescence index (MFI) was
recorded as a measure of VSA-specific IgG reactivity. Each
assay was repeated three times on separate days with sim-
ilar results. A batch of uninfected erythrocytes was ana-
lysed to exclude IgG binding to erythrocyte antigens.
The wet immuno-fluorescent preparations were per-
formed following the staining procedure described for the
flow cytometry assays with a few modifications: DNA was
labelled with 10 ng/ml DAPI and in the final staining step
0.5 μl Streptavidin-Alexa®488 was used instead of FITC
(Invitrogen, Paisley, UK). Images were taken using a TE
2000-E Nikon Eclipse confocal microscope, using a 100×
Apoplan oil immersion objective. Images were captured
using the EZ-C1 Gold imaging system (version 3.30).
Images of each parasite preparation stained with
VAR2CSA-specific antibodies, peptide-specific antibodies
or control antibodies were captured without adjusting
pixel dwell time, laser-power nor photomultiplier gain.
Results
Multiple linear VAR2CSA regions have affinity for 
proteoglycans
The exon1 of var2csa has 9171 bp and was PCR amplified
and cloned into the T7select 415-1b phage vector. The
plasmid was propagated and the insert containing the
whole  var2csa  exon1 was cut out and digested with
DNase1 to generate 200 bp fragments. The var2csa frag-
ments were used to create a T7 Phage display library as
described in the material and methods section. This vector
is described to display 415 copies of peptides on the sur-
face of the T7 capsid [31].
To ensure that all parts of VAR2CSA exon1 were present in
this constructed library a number of clones were
sequenced before biopanning. No sequences were over-
represented and sequences belonging to all six DBL
domains were present in the library (Figure 1A, black).
The  var2csa  phage display library was biopanned four
rounds on: CHO cells (two independent assays); human
placental choriocarcinoma cell line BeWo (four inde-
pendent assays); bovine CSA (two independent assays);
biotinylated CSA (two independent assays) and chondroi-
tin sulfate proteoglycans of human placenta (CSPG) (two
independent assays). Control biopannings were done on
ELISA plates coated with BSA (Figure 1A, Blocking Bf,
blue). From each assay 15 clones were sequenced. Figure
1 shows the frequency by which different phages express-
ing particular VAR2CSA regions were identified after the
different types of biopanning. Biopanning on CSA
resulted in enrichment of a single region (20% of all
phages) corresponding to a peptide sequence in DBL3
(Figure 1A, green). CSA coated directly on ELISA plates
might not be very efficient; therefore the biopanning was
subsequently repeated using biotinylated CSA (bCSA).
This resulted in enrichment of phages representing
sequences present in DBL1, DBL2 and DBL4 (Figure 1A,
red). In addition, biopanning on human placental CSPG
resulted in enrichment of phages representing DBL4 and
DBL5 sequences (Figure 1A, yellow). However, the DBL4
sequence was also present in 18% of the control BSA bio-
pannings (Figure 1A, blue). To further identify proteogly-
can-binding regions, the VAR2CSA phage display library
was biopanned on BeWo and CHO cells expressing CSPG
and CSA, respectively (Figure 1B). Enrichment of phagesMalaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
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expressing peptides from DBL2, DBL3, DBL4 and DBL5
was seen. Again the DBL4 sequence was also detected in
the phages from the control biopanning. DBL2 and DBL3
phages binding to the GAG expressing cells contained
VAR2CSA sequences that overlapped with the sequences
identified by the CSA biopanning. The DBL5 sequence
overlapped with the clone identified by CSPG biopan-
ning. In summary, five relatively short stretches of
VAR2CSA appeared to bind soluble GAGs as well as GAGs
expressed on cells. No none-DBL regions (i.e. NTS, ID1 or
ID2) were identified as GAG binding.
Mapping the phage display selected regions on models of 
VAR2CSA DBL domains and comparing with the previous 
described surface-expressed epitopes
Structural models of VAR2CSA 3D7 DBL domains have
previously been produced using the solved DBL structures
in EBA-175 and Pkα-DBL as templates [36]. As part of pre-
vious work we identified regions on native VAR2CSA,
which were accessible to antibodies [26,36]. In the current
study, the CSA-binding regions defined by the phage dis-
play screening were mapped onto the models and com-
pared to the previous findings (Figure 2). Interestingly, in
Frequency of identifed phages sorted according to the identity of the VAR2CSA region and the method of biopanning Figure 1
Frequency of identifed phages sorted according to the identity of the VAR2CSA region and the method of bio-
panning. The var2csa phage display library was biopanned four rounds on each of the following: biotinylated CSA (A, red); 
Chondroitin sulfate proteoglycans of human placenta (CSPG) (A, yellow); bovine CSA (A, green); CHO cells expressing CSA 
on the surface (B, pink) and human placental choriocarcinoma cell line BeWo (B, blue). Control biopannings were done on 
ELISA plates coated with BSA (A, blue) and the original library was sequenced prior to selection to confirm the presence of 
sequences belonging to all domains (A, black). For each assay 15 CSA-binding clones were sequenced. Each coloured bar indi-
cates the VAR2CSA sequence expressed by the selected phage on the x-axes and the frequency by which the sequence was 
detected by sequencing on the y-axes. The length of the coloured bar indicates the length of the VAR2CSA sequence in the 
selected phage. The VAR2CSA regions most often expressed by the CSA-binding phages are shaded in grey (P1-P5).Malaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
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DBL2, DBL3 and DBL5 there was a high degree of overlap
between the CSA-binding regions and the surface-exposed
regions (Figure 2, green). Peptides residing in DBL1 and
DBL4 did not map to the predicted surface exposed
regions. All mapped regions, except the DBL1 region,
mapped to the S2 subdomain of the DBL domains. The
CSA-binding regions mapped in DBL2 and DBL5 are in
close vicinity to the chemokine-binding site region of
Pkα-DBL Duffy [37].
Synthetic peptides representing P1-P5
Seven peptides, corresponding to VAR2CSA regions P1-P5
(Figure 1 and Table 1), were synthetized and biotinylated
to evaluate their ability to bind CSA in an ELISA assay. For
the ELISA based CSA-binding assay: plates were coated
with CSA and binding was measured using a streptavidin-
conjugated peroxidase-antibody. In order to determine
the background binding and detect the true signal, half of
the plate was not coated with CSA but all the subsequently
steps were performed equally in the whole plate. Using
Structural models of VAR2CSA DBL domains showing surface-exposed regions and GAG binding regions Figure 2
Structural models of VAR2CSA DBL domains showing surface-exposed regions and GAG binding regions. The 
surface-exposed epitopes previously determined by depleting female IgG plasma on parasites expressing VAR2CSA are shown 
in blue. The GAG binding regions identified by phage display assays are shown in yellow. The overlap of surface-exposed 
regions and GAG binding regions is shown in green.Malaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
Page 8 of 11
(page number not for citation purposes)
this assay P2b (DBL2) showed specific binding to CSA
compared to the background and additionally did not
bind to CSC (Figure 3, red curves). A non-VAR2CSA con-
trol peptide (Table 1, PC) was used (Figure 3, blue curves)
and didn't show binding to any of the GAGs.
Antibodies specific to the DBL2X peptide react with native 
VAR2CSA on the surface of infected erythrocytes
Sera from rabbits immunized with recombinant
VAR2CSA DBL domains [34] were tested for reactivity
against the six peptides. Rabbits immunized with recom-
binant whole domain DBL1 and DBL4 did not react with
the peptides from these domains (P1 and P4). Rabbits
immunized with recombinant whole domain DBL2,
DBL3 and DBL5 reacted with P2, P3, and P5, respectively.
Peptide-specific antibody reagents were then produced by
affinity purifying rabbit antibodies on the peptides. The
affinity-purified antibodies were tested in flow cytometry
for reactivity with native VAR2CSA expressed on erythro-
cytes infected with the NF54 parasite strain (Figure 4A).
Anti-P2c peptide specific antibodies stained the surface of
the infected CSA-binding erythrocytes. In addition, the
reactivity was observed by wet IFA (Figure 4B). The surface
staining determined by IFA showed a dotted pattern typi-
cal of PfEMP1 staining. We were unable to detect binding
with P2a, P2b, P3 and P5 specific antibodies.
Discussion
Malaria parasites causing PAM have been shown to bind
to glycosaminoglycans in the intevillous space of the pla-
centa. These parasites also bind specifically to bovine CSA
[18], CSPG [38] as well as BeWo [39] and CHO cells hav-
ing CSPG on the surface [18]. The binding between the
parasite and the placental CSPG is most likely mediated
through the parasite expressed protein, VAR2CSA.
VAR2CSA is a large multidomain protein and for vaccine
development it is important to define which regions of
VAR2CSA are responsible for the interaction with CSPG.
In the present study a var2csa phage display library was
biopanned on five different CSA containing targets
(bovine CSA, bovine bCSA, human placental CSPG,
BeWo and CHO cells) in 12 independent experiments.
Five regions of VAR2CSA repeatedly showed affinity for
the different CSA preparations. The CSA-binding peptides
identified with the phage display approach were based on
the linear sequence of VAR2CSA. However, the CSA bind-
ing region might be conformational and involve peptides
from several domains. It is preferable that results obtained
by phage display assays are confirmed by showing that
peptides corresponding to the identified regions also pos-
sess binding capacity. The var2csa phage display library
used in this study was constructed from DNA fragments of
100–150 bp, and the corresponding peptides are thus 34–
75 aa. These long peptides were difficult to synthetize and
were unstable in solution and we thus had to divide some
of the phage regions into several synthetic peptides. Fur-
thermore, the structure of peptides in solution might be
very different from peptides bound to a phage. These fac-
tors could explain why only one out of seven synthetic
peptides could have its binding to CSA confirmed.
DBL2, DBL3 and DBL5 domains of VAR2CSA have previ-
ously been shown to bind to CSA [24-26] and the surface-
exposed regions within these domains have been mapped
[26,36]. Three of the five peptides are located on surface-
exposed parts of the previously described CSA-binding
domains and two of these peptides map to regions on the
DBL domains, which are in close proximity to the ligand-
binding region of Pk-alfa-DBL [37]. These findings show
an agreement between two independent approaches,
which strengthens the present results. No CSA-binding
epitopes were found in the highly polymorphic DBL6
domain, which previously has been shown to bind CSA
indicating the presence of conformational CSA binding
regions in this domain [25].
Region P2 was very long and had to be divided into two
peptides for synthesis. The first part of the region showed
specific CSA binding (P2b, Figure 3) and the second part
of the region (P2c) using peptide affinity purified anti-
bodies in IFA, confirmed that the CS- binding peptide
region present in DBL2 was in fact surface-exposed in
native VAR2CSA expressed on IE (Figure 4).
The affinity-purified antibodies did not inhibit parasite
binding to CSA (data not shown), but this is not surpris-
ing as multiple epitopes/domains of VAR2CSA are sug-
gested to be independently involved in CSA binding [24-
26]. However, it is possible that all domains of VAR2CSA
contribute to a common CSA binding groove, either in a
monomeric form or a di-polymeric form, such a glycan
binding groove has been shown to be present in a reverse-
hand shake dimer of EBA-175 [40]. Individual peptides
and domains may have low affinity for binding to CSA,
whereas high affinity is only achieved by the assembly of
the entire binding site. Chrystallography and structure
elucidation of an entire VAR2CSA molecule is not techni-
cal feasible with current technology, therefore a complex
multi-domain CSA-binding site is difficult to identify.
Current methods of identifying the CSA-binding regions
of VAR2CSA primarily employ the ability of peptide-spe-
cific antibody reagents to inhibit parasite adhesion. If
multiple sites are involved in adhesion, screening with
single specificity antibodies might not suffice to identify a
vaccine construct. By combining the knowledge from:
recombinant DBL binding assays; parasite anti-adhesion
assays using domain-specific antibodies; epitope map-
ping approaches and phage display approaches, we might
be able to construct a chimeric vaccine, encompassing dif-
ferent CSA binding regions and important antibodyMalaria Journal 2008, 7:104 http://www.malariajournal.com/content/7/1/104
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epitopes. The phage display approach described here is
the first study that attempts to find smaller CSA binding
regions within the DBL domains of the vaccine candidate
VAR2CSA.
Conclusion
Phage display was used to identify GAG binding linear
regions of VAR2CSA. Five regions located in five different
domains were found to have affinity for both immobi-
lized CSA and CSA expressed on the surface of cells. The
most frequently observed GAG binding phages mapped
to DBL2, 3, 4 and DBL5, and except DBL4 all these
domains have been shown to bind CSA in vitro. These
results are supported by data published by Andersen and
others [36], demonstrating that the phage display defined
CSA-binding regions in DBL2, 3, 5 all locate to areas of
VAR2CSA that appear to be exposed on the native mole-
cule. The DBL2 CSA binding peptide showed specific
binding to CSA and affinity-purified antibodies against
the same phage display identified region reacted with the
surface of infected erythrocytes. This work is the first step
in defining small regions of VAR2CSA, which can be used
in an adhesion blocking sub-unit vaccine protecting preg-
nant women against PAM.
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